Compare CDZIP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZIP | RZLT |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 187.3M |
| IPO Year | N/A | N/A |
| Metric | CDZIP | RZLT |
|---|---|---|
| Price | $19.50 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | N/A | ★ 15.5M |
| Earning Date | N/A | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.07 |
| 52 Week High | N/A | $11.46 |
| Indicator | CDZIP | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 33.14 |
| Support Level | $19.05 | $1.87 |
| Resistance Level | $19.83 | $2.43 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 62.51 | 44.24 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.